AlzeCure Pharma AB (publ) announced that a new scientific article on preclinical results supporting antidepressive effects with NeuroRestore ACD856 has been published. The article, titled "Ant antidepressantant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept", was published in the journal Psychopharmacology and corresponding author is Johan Sandin, Chief Scientific Officer at AlzeCure Pharma. Co-authors are Nather Madjid, Veronica Lidell, Gunnar Nordvall, Maria Lindskog, Sven Ove Ogren and Pontus Forsell.

The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various preclinical models. These findings are also supported by data showing that ACD8 56 affects levels of relevant neurotransmitters in the brain. Furthermore, it was shown that other antidepressants also seem to mediate their effects via the same target mechanism as ACD856 and that these can be combined for an even better effect.

Depression is an area of great medical need. That ACD856 exhibits potent antidepressant effects in these preclinical models broadens and strengthens the commercial possibilities of the NeuroRestore project that are now preparing for Phase II". The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various preclinical models.

These findings are also supported by data showing that ACD856 affects levels of relevant neurotransmitters in the brain. Furthermore, it was shown that other antidepressants also seem to mediate their effects via the same target mechanism as ACD856 and that these can be combined for an even better effect.